A number of other research analysts also recently issued reports on the stock. S&P Global set a €66.00 ($75.00) target price on shares of STADA Arzneimittel AG and gave the company a neutral rating in a research report on Monday, May 29th. Warburg Research set a €66.00 ($75.00) target price on shares of STADA Arzneimittel AG and gave the company a sell rating in a research report on Saturday, May 20th. Kepler Capital Markets set a €62.50 ($71.02) target price on shares of STADA Arzneimittel AG and gave the company a sell rating in a research report on Thursday, June 22nd. Finally, Commerzbank Ag set a €66.00 ($75.00) price objective on shares of STADA Arzneimittel AG and gave the company a neutral rating in a report on Tuesday, June 20th. Five investment analysts have rated the stock with a hold rating, STADA Arzneimittel AG presently has a consensus rating of Hold and an average target price of €64.90 ($73.75).
Shares of STADA Arzneimittel AG (ETR SAZ) opened at 65.339 on Tuesday. STADA Arzneimittel AG has a 52 week low of €41.40 and a 52 week high of €67.60. The firm has a 50-day moving average price of €64.28 and a 200-day moving average price of €57.33. The stock has a market cap of €4.07 billion and a price-to-earnings ratio of 38.571.
WARNING: This news story was originally published by BBNS and is owned by of BBNS. If you are viewing this news story on another publication, it was illegally copied and republished in violation of U.S. & international copyright and trademark law. The original version of this news story can be read at https://baseballnewssource.com/markets/independent-research-gmbh-reiterates-66-25-price-target-for-stada-arzneimittel-ag-etrsaz/1194090.html.
STADA Arzneimittel AG Company Profile
Stada Arzneimittel AG is a Germany-based holding company active in the pharmaceutical sector and healthcare market. The Company develops and markets products with off-patent active pharmaceutical ingredients. The Company’s primary business segments are Generics and Branded Products. The Generics segment comprises low-priced and active-ingredient products.
Receive News & Ratings for STADA Arzneimittel AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STADA Arzneimittel AG and related companies with our FREE daily email newsletter.